Synergy Health plc Invests 18 Million GBP (US$30 Million) To Expand Global Applied Sterilisation Technology Capacity
Synergy Health, a leading provider of outsourced sterilisation and laboratory services to the healthcare industry, is investing £18 million (US$30M) to expand capacity in its Applied Sterilisation Technology (AST) division. The expansion plans are expected to increase revenues by approximately £33 million (US$55 million) over the coming 3 years, in line with previous guidance.
Europe: Gamma capacity in Europe is being increased across three facilities to accommodate new contract wins. In Ede (the Netherlands) the facility will be expanded by approximately 50%, in Radeberg (Germany) capacity will be increased by 30% and a new gamma pallet facility will be constructed in Bradford (UK) more than doubling capacity. In addition Synergy is extending its network of laboratories to Radeberg to provide microbiological, food and allergen testing services.
Asia: The Ethylene Oxide facility in Kuala Ketil (Malaysia) will receive a fourth 12 pallet chamber expanding capacity by 25%.
The Americas: Synergy will start construction on its sixth e-beam facility in the San Francisco North Bay area having secured contracts to underpin the new operation. This facility, targeted for completion April 2015, will augment two existing e-beams located in San Diego and provide customers with additional business continuity assurance. In addition, construction has started on a new laboratory in the existing San Diego facility. The previously announced additional e-beam in Saxonburg PA remains on schedule to commence operations March 2015.
"We are pleased to support the increasing demand from our multinational medical device customers for our sterilisation services. Following the construction of the e-beam in San Francisco, Synergy will have the largest global network of sterilisation facilities serving its customers across 15 countries in Europe, Asia, South Africa and the Americas," said Andrew McLean, CEO Applied Sterilization Technologies & Laboratories.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance